The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Mercer also said 64% of U.S. employers with over 20,000 employees covered weight-loss drugs in 2024, compared with 56% last ...

In 2024, the percentage of U.S. employers covering weight-loss drugs has increased, with notable rises among larger employers ...

This investor's weighing up a couple of world-class companies for his Stocks and Shares ISA after the US election sparked a sell-off.

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.

Novo Nordisk rose after the Danish giant launched its Wegovy weight-loss product in China. Merck reported promising trial results for a new, easier-to-administer formulation of its blockbuster cancer ...

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...